Correction: GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors


This article has been corrected since it was first published. The Y axis of Figure 3B has been updated to ‘CD11b IHC prevalence (% positive)’.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2021;9:e003005corr1. doi:10.1136/jitc-2021-003005corr1